Objective: To describe a novel and distinct variant of progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with antibodies directed against dipeptidyl peptidase-like protein 6 (DPPX), a regulatory subunit of the Kv4.2 potassium channels on the surface of neurons.
Serologic studies. DPPX antibodies were detected using a recombinant, cell-based indirect immunofluorescence assay as previously reported. 10 Other applied biochip mosaics (Euroimmun, Lübeck, Germany) contained frozen tissue sections (rat: hippocampus, cerebellum; monkey: cerebellum, nerves, intestine, and pancreas) and recombinant cell substrates, each expressing a different neuronal antigen (NMDAR-NR1a/NR2b, AMPAR-GluR1/GluR2, GABAR-B1/B2, LGI1, CASPR2, GLRA1b, GRM1, GRM5, MOG, Tr/DNER, AQP4, GAD65, GAD67, ZIC, ARHGAP26, Yo, amphiphysin, Hu, Ri, Ma1, Ma2, CV2, Sox-1, and recoverin). A detailed methodologic description of the detection of antibodies and titers by biochip mosaics is provided on the Neurology ® Web site at Neurology.org and elsewhere. 11 Samples were also tested by using the radioimmunoprecipitation assay for VGKC-complex antibodies (RSR Ltd., Cardiff, UK), Euroimmun line blot assays (EUROLINE Neuronal Antigens Profile 2 and Profile PLUS RST: amphiphysin, CV2, Ma2, Ri, Yo, Hu, recoverin, Sox-1, titin), Euroimmun Anti-Tissue Transglutaminase ELISA, Anti-Gliadin GAF-3X ELISA, Colitis Ulcerosa Mosaic 1, and Crohn Mosaic 1, according to the manufacturers' instructions.
Calculation of the antibody index allows detection of an intrathecal synthesis of a specific antibody, with values .4 considered pathologic if antibody titers are used for calculation (reviewed in detail in reference 12).
Standard protocol approvals, registrations, and patient consents. The study was approved by the local ethics committee, and all patients gave written informed consent.
RESULTS
The main clinical and paraclinical findings of the patients are summarized in the table.
Case reports. Case 1. This 16-year-old schoolboy presented in June 2009 with a 1-year history of unsteadiness of the right arm and excessive startle on noise or touching the trunk. Symptoms had developed within a month without any particular antecedents. Recently, he had developed scoliosis. Examination revealed downbeat nystagmus, broken pursuit, and incomplete suppression of the vestibuloocular reflex on fixation. The head retraction reflex was distinctly positive with poor habituation. Finger-to-nose testing disclosed an action tremor in both hands. He had marked S-shaped scoliosis of the thoracic spine, trunk stiffness when bending forward (figure 1A), and slightly rigid muscle tone with exaggerated deep tendon reflexes in the legs, but no pyramidal signs. CSF showed mild lymphocytosis with presence of plasma cells (28 cells/mL; normal ,5) and intrathecal synthesis of immunoglobulin (Ig) G and IgM, without evidence of any infectious agents. Electrophysiology revealed continuous motor unit activity in the thoracic paraspinal muscles. Tactile and acoustic stimulation evoked abnormal jerky reflex responses in the neck and paraspinal muscles with a latency slightly above that of the blink reflex and without obvious habituation (figure 2). Electrooculography (EOG) confirmed a cerebellar eye movement disorder with broken pursuit, spontaneous downbeat nystagmus, and gaze-evoked horizontal nystagmus. MRI of the brain and EEG were normal. Whole-body [ 18 F]fluorodeoxyglucose (FDG)-PET did not show either a neoplasm or abnormalities of brain glucose metabolism. When unclassified neuropil antibodies (later identified as DPPX antibodies) were detected, 2 treatment attempts with IV methylprednisolone (500 mg for 3 days with oral tapering over 6 weeks) were undertaken but produced only a marginal effect. Symptomatic treatment with benzodiazepines gave substantial relief from excessive startle. However, within 1 year, the hand tremor had worsened considerably and he had developed tremor of the head and voice. At follow-up 21 months after symptom onset, normal walking was unimpeded, but tandem gait and standing on one leg were impossible. Physical status was otherwise unchanged. Neuropsychological testing identified mild deficits in long-term memory and verbal fluency. A second lumbar puncture disclosed persistent lymphocytosis (11 cells/mL) and intrathecal synthesis of IgG and IgM. IV immunoglobulin (IVIg; 2 cycles at 2 g/kg body weight per day over 3 or 2 days, respectively) did not improve the condition to any considerable extent, but 5 sessions of plasma exchange transiently reduced both hyperekplexia and the hand and voice tremor. Recurrence of symptoms prompted initiation of B-cell-depleting therapy with rituximab (4 cycles every 3 months, each 375 mg/m 2 ) starting 42 months after symptom onset. This led to a gradual improvement as substantiated by the Scale for the Assessment and Rating of Ataxia, 13 his handwriting, and the EOG recordings ( figure 3 ).
Case 2. At age 27 years, this previously healthy carpenter noticed that, while working on a scaffold, a gentle breeze sweeping over his forehead suddenly made him stiff. Subsequently, the stimulus-sensitive region expanded over the whole head, neck, and trunk, and transient muscular stiffness became more and more intense, lasting, and jerky. Eventually, the jerky spasms became so violent that he was no longer able to work in this occupation. Approximately 1 year after symptom onset, he developed Raynaud phenomenon to such an extent that he had to start wearing gloves in early autumn and use gel pouches in his pockets to warm his hands. After another 4 years, constipation developed and he could only defecate once a week. Six years after onset, he experienced vertigo lasting for a few months and since then he has had blurred vision on external gaze and acrophobia. Recently, he developed paraesthesia and allodynia on his chest and pruritus on his neck, where the skin became thickened and purple in color due to frequent scratching. He also felt that the trunk muscles became constantly stiff between the spasm attacks. Examination 8 years after onset showed jerky reflex spasms of the head and trunk on tactile stimulation, particularly of his forehead and back; in fact, merely the examiner's breath sufficed to evoke the spasms. Eye movements were abnormal with broken pursuit and nystagmus on external gaze. He also presented dysdiadochokinesis and mirror movements of the hands, a minor tremor on finger-to-nose testing, and mild ataxia on heel-to-shin testing. Gait was slightly broadbased with insecure tandem gait, and balance standing and hopping on one foot were impaired. The remainder of the examination was unremarkable. MRI of brain and spine and EEG were normal. EOG confirmed the clinical findings of broken pursuit and showed an inconstant, dissociated nystagmus on external gaze. The first lumbar puncture showed mild lymphocytosis (10 cells/mL) and unmatched oligoclonal bands, and neuropil antibodies of unknown specificity were detected in the serum. Oral treatment with low-dose methylprednisolone was initiated, and additional therapy with clonazepam further alleviated other symptoms. The patient was then able to resume work because the jerky reflex spasms were much milder; his bowel movements had also normalized. Repeated CSF analysis identified plasma cells with normal cell count and unmatched oligoclonal bands. Whole-body FDG-PET did not reveal a tumor. The clinical course was stable for 2 years with the abovementioned treatment regimen. Recently, however, the patient noticed a constant stiffening of the back muscles, an increase of the jerky reflex spasms, and a worsening of the constipation. A course of IVIg was administered without noticeable effect, and a trial with rituximab is planned. Case 3. This patient was identified retrospectively because of the clinical features he shared with the previous patients. Aged 26 years, this administrative officer fell ill with unexplained diarrhea and weight loss of 10 kg. Subsequently he experienced several relapses of unclassified ocular motor disturbance and hyperhidrosis, which evolved within 3 years to a chronicprogressive course. By then, broken pursuit and gaze-evoked nystagmus with diplopia on lateral gaze had developed. He had severe trunk stiffness with scoliosis ( figure 1B) and marked hyperekplexia on acoustic and tactile stimulation of the head, trunk, and limbs. Jerks were even provoked by unexpected movements of the examiner. Vestibuloocular reflex suppression was impaired. Cerebellar signs involved slurred and scanning speech as well as gait and limb ataxia. Additional symptoms comprised intense allodynia and neurogenic pruritus, memory and attention deficits, hyperreflexia, urinary retention, and erectile dysfunction. Initially he responded somewhat to high-dose steroids and to IVIg (2 g/kg body weight per day over 5 days). However, the effects did not last long and treatment was discontinued. When the disease progressed, cyclophosphamide and plasma exchange (5 sessions) treatment was initiated, again without any effect. During the course of the disease, lasting approximately 18 years, he lost approximately 40 kg and became severely disabled, depending on a walker for perambulation. Later on, he experienced frequent falls, and because of episodes with loss of consciousness, epilepsy was suspected. He developed a spastic tetraparesis and generalized myoclonus; due to dysphagia, he recurrently contracted severe pneumonia requiring intensive care treatment, which eventually led to death.
Diagnostic workup revealed mild CSF lymphocytosis (8-11 cells/mL on repeated lumbar punctures) with unmatched oligoclonal bands in CSF, continuous motor unit activity of paraspinal muscles, and exaggerated cutaneomuscular reflexes; results of extensive tumor screening, including whole-body FDG-PET, were unremarkable, and MRI of the brain and the spine were initially normal. Seventeen years after onset, MRI of the brain disclosed mild cerebellar atrophy.
Antibody tests. Serum reactivity with the cerebellar cortex, the hippocampus, and the myenteric plexus was detected by immunohistochemistry in all 3 patients.
Cerebellar staining was most prominent in the granule cell layer, showing a patchy fluorescence pattern, with antibodies binding mainly to the periphery of granule cells and to cerebellar glomeruli. The cerebellar molecular layer showed a weaker homogeneous labeling, while staining of Purkinje cells and white matter could not be detected (figure e-1, A-C).
In the hippocampal cornu ammonis subfields, a homogeneous neuropil staining pattern was detected in areas containing basal and apical dendrites of pyramidal cells (stratum oriens, stratum radiatum, stratum lacunosum moleculare). In contrast, the somata of pyramidal cells were only weakly stained. Characteristically, the strongest immunoreactivity was observed in the stratum lucidum where the mossy fibers (dentate granule cell axons) are located (figure e-1D). In the dentate gyrus, the somata of granule cells were only faintly labeled. However, dense immunostaining was found in the stratum moleculare and hilus containing the dendrites and axons of dentate granule cells, respectively (figure e-1, E and F). Using a new cell-based assay with HEK293 cells expressing DPPX, DPPX antibodies were identified in the serum of patient 1 (titer of 1:10,000 on first testing; figure e-2). By adding DPPX antigen to the serum sample before incubation with the cell and tissue substrates, specific reactivity was substantially abrogated, thus confirming DPPX as the antibodies' target ( figure 4) .
At retrospective analysis of stored follow-up samples of this patient, DPPX antibodies were also detected in the CSF with a DPPX antibody index of 15. Moreover, a correlation was found between DPPX antibody titers in serum/CSF and clinical response to therapy ( figure 3) . DPPX antibodies were also detected in the serum and the CSF of patient 2 (titers of 1:3,200 in serum, and 1:320 in CSF before immunotherapy, serum titer of 1:320 at follow-up; DPPX antibody index 5 10) and patient 3 (titers ranging from 1:320 to 1:1,000 in serum, and 1:100 in CSF; DPPX antibody index 5 9). In addition, serum reactivity against the myenteric plexus was observed ( figure 4) .
In all 3 cases, no other anti-neuronal antibodies, antibodies associated with celiac disease (anti-gliadin, anti-tissue transglutaminase), or forms of chronic inflammatory bowel disease (anti-goblet cells, antiexocrine pancreas/CUZD1/GP2, anti-Saccharomyces cerevisiae, anti-neutrophil cytoplasmic antibodies) could be identified by applying the assays mentioned in the Methods section. DISCUSSION DPPX antibodies have been described very recently in 4 patients with protracted encephalitis and symptoms of CNS hyperexcitability comprising tremor, myoclonus, prominent hyperekplexia, and cerebellar signs such as ataxia and nystagmus. 9 Herein, we report another 3 patients presenting with a distinct syndrome characterized by the triad of trunk stiffness, hyperekplexia, and marked cerebellar ataxia in whom the new antibodies against DPPX were detected. The patients' phenotype fits the 
Figure 3 Correlation between DPPX antibody titers and disease activity
Fifteen-month follow-up of antibody (ab) titers (patient 1) in parallel with therapeutic interventions as indicated. Disease activity is represented by scores on the Scale for the Assessment and Rating of Ataxia (SARA). 13 DPPX 5 dipeptidyl peptidase-like protein 6; IVIg 5 IV immunoglobulin. clinical criteria for PERM, which shares a variety of clinical and immunologic characteristics with SPS but also features firm neurologic signs such as eye movement disorders, ataxia, or epilepsy, and in some cases, a more aggressive disease course. 1, 2 Clinical presentation in our patients was dominated by hyperekplexia and ataxia of eye, limb, and trunk movements, while trunk stiffness with secondary scoliosis (patients 1 and 3) was less incapacitating. Hyperekplexia was associated with startle reflexes to tactile (patients 1-3), acoustic (patients 1 and 3), and even visual stimulation (patient 3) with short response latencies in the neck muscles. Cerebellar ataxia covered the full range of cerebellar eye movement disorders (up-or downbeat nystagmus, gazeevoked nystagmus, broken smooth pursuit, dysmetric saccades, and poor suppression of the vestibuloocular reflex during fixation). Trunk and limbs were less severely involved. Further signs comprised somatosensory disturbances and dysautonomia (patients 2 and 3). The disease began insidiously, partly with relapses, and ran a progressive course. Overall severity ranged from moderate disability to intensive care and death of patient 3 approximately 18 years after the first symptoms developed. Notably, no other autoantibodies, including those known to be associated with the spectrum of SPS, acquired hyperekplexia, or cerebellar ataxia, were found in our patients.
Whereas the first DPPX antibody-positive patients had severe encephalitis with seizures, psychiatric symptoms, decreased levels of consciousness, and a more acute and severe course, 10 shared features comprise signs of cerebellar ataxia and symptoms compatible with CNS hyperexcitability, particularly hyperekplexia and myoclonus. As in the original publication, 10 our patients had CSF lymphocytosis during the course of the disease and showed evidence of intrathecal IgG synthesis. High titers of the new DPPX antibodies were detected not only in the serum but also in the CSF of our patients. In particular, the high DPPX-specific antibody indices represent intrathecal synthesis. Taken together with the inflammatory CSF profile, this indicates that DPPX antibodies are produced in the CSF compartment, which may partly explain the observed need for escalated and continuous immunotherapy. In fact, according to the experience with the previously described cases 10 and our case series, it appears that patients respond favorably to immunotherapy, but constant and aggressive treatment seems to be required.
The antigen DPPX, a membrane glycoprotein with a large extracellular domain, is an auxiliary subunit of neuronal Kv4.2 channels. 8 DPPX enhances the opening probability and single-channel conductance of Kv4.2 channels, facilitates intracellular trafficking of Kv4 proteins, and increases the surface expression of Kv4.2 channels. 14 Loss of DPPX results in hyperexcitable dendrites with enhanced dendritic action potential back-propagation, calcium electrogenesis, and induction of synaptic long-term potentiation. 15 Both DPPX and Kv4.2 proteins are localized in hippocampus, cerebellar cortex, striatum, and pontine nuclei. 8 DPPX is also expressed on the hippocampal mossy fiber axons, which lack Kv4.2 proteins, suggesting that DPPX proteins may have additional functions unrelated to Kv4.2. 8 Although the exact pathogenetic mechanisms are currently elusive and await further investigation, the fact that the antigen is a surface protein renders a pathogenic role of DPPX antibodies readily conceivable. Arguments for a pathogenic role of DPPX antibodies in our patients include treatment response to immunotherapy with correspondingly decreasing antibody titers, as shown for patient 1, and the impression that the clinical symptoms and signs correlate with the distribution of the antigen. The tissue staining pattern produced by our patients' antibodies was in accordance with the previously described distribution of DPPX protein. 8 Antibody interference with sites of DPPX enrichment 8 could explain the cerebellar ataxia, mnestic deficits, and hyperekplexia observed in our patients. DPPX is also expressed by the myenteric plexus neurons, and 3 of the 4 patients from the first study had severe prodromal diarrhea and marked weight loss, 10 as did our patient 3; patient 2 had marked constipation, which resolved with steroid treatment. Sera from all of our patients displayed reactivity against the myenteric plexus, and no other serologic evidence was found to support other potential causes such as chronic inflammatory bowel or celiac disease; thus, DPPX antibody interference with gastrointestinal functions seems plausible.
To tentatively explore the association of DPPX antibodies with the SPS spectrum, we tested sera of 8 other patients with SPS, PERM, or acquired hyperekplexia (for details, see supplemental data) but did not detect DPPX antibodies in any of these cases. None of these patients, however, displayed the extended clinical characteristics as described above for the DPPX antibody-positive patients, i.e., the combination of cerebellar ataxia with nystagmus, prominent hyperekplexia, and trunk stiffness, in the context of a chronic disease course. These preliminary results may imply that the DPPX antibody is not a "unifying antibody" in the SPS spectrum disorders, but rather suggest a close association with the distinct syndrome as described above.
Further studies are certainly needed to determine the role of DPPX antibodies at the molecular level, the exact pathogenic mechanisms of action, and the associated clinical manifestations. Our patients, however, highlight an expanding clinical and immunologic spectrum of PERM and illustrate the importance of serologic screening tests to identify antibody-positive patients who may benefit from immunotherapy.
